The annual incidence of both pancreatic and liver cancer is outlined below, which translates to a global opportunity of more than US$2 billion for pancreatic treatment and US$1.4 billion for liver cancer assuming a US$25,000 price per dose of OncoSilTM.
https://www.google.com/amp/s/finfeed.com/small-caps/biotech/oncosil-verge-ce-mark-approval/amp/
The annual incidence of both pancreatic and liver cancer is...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.002(16.7%) |
Mkt cap ! $52.97M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $170.2K | 13.08M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1581235 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 9880504 | 9 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |